Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease

The Endocrine Society has accepted the NETest as a biomarker for microscopic liver disease (minimal residual disease) in neuroendocrine tumors for their thematic issue on Neuroendocrinology in 2019.

The data identifies that “Emerging molecular liquid biopsies (e.g., NETest) provide a substantially improved threshold for disease detection.” 

Click here to read more